Business Wire

Making Science Announces Sale of its Cloud and Cybersecurity Unit to Lutech

8.10.2025 11:24:00 EEST | Business Wire | Press release

Share

Making Science Group, S.A. (BME Growth: MAKS) (“Making Science”), a leading digital marketing and technology consulting firm, and Lutech S.p.A. (“Lutech”), a digital leader headquartered in Italy, announced today that they have entered into an agreement pursuant to which Making Science will sell its Cloud and Cybersecurity business unit in Spain to Lutech.

The transaction enables Making Science to concentrate its resources on consolidating its leadership in its core digital marketing, AdTech, and artificial intelligence segments.

For Lutech, the acquisition represents a new strategic expansion of its presence in the Spanish market and an enhancement of its service portfolio with a team of highly specialized professionals.

TRANSACTION OVERVIEW AND RATIONALE

The transaction will be effected by the sale and purchase of Making Science’s legal entities in Spain that operate in the cloud infrastructure, enterprise software development, and cybersecurity services segments.

The consideration payable under the transaction is a maximum of €26 million and consists of an upfront payment plus an additional payment to be paid in the first half of 2026, based on actual 2025 EBITDA.

Closing of the transaction, expected in Q4 2025, is subject to foreign direct investment approval in Spain and the fulfillment of customary conditions precedent for this type of transaction.

For Making Science, the divestment allows the company to focus its resources and management capabilities on its core business units: Digital Marketing Services, AdTech, and RAISING (its Artificial Intelligence technology division). These are the segments where the company has developed distinct competitive advantages and holds the greatest opportunities to become a global leader in both categories, maximizing international expansion and value creation.

For Lutech, this acquisition is another significant step in its international growth strategy. It establishes a strong foothold in the Spanish market, incorporating a talented team with a proven track record and a solid client base which further strengthens the presence of Lutech in Spain with Lutech Sapimsa and Cimworks. The addition of this unit strengthens Lutech's capabilities in high-demand areas such as cloud services, custom software, and cybersecurity, enhancing its offering for clients across Europe.

Lutech was advised by PCB Partners, DLA Piper and EY. Making Science was advised by GP Bullhound and Gómez-Acebo & Pombo.

A CONTINUED PARTNERSHIP

The transaction is structured to ensure complete operational continuity for all current clients and the seamless integration of the expert team into Lutech. Furthermore, Making Science and Lutech confirmed a strategic alliance whereby Making Science will continue to be an important customer of this business unit, ensuring that its clients maintain seamless access to the differentiated skillset and technology of its former cloud and cybersecurity unit.

Lutech is a leading Italian technology group in the development and implementation of enterprise solutions, with a proven track record in the management and development of high-performance technical teams. Its profile guarantees not only continuity in service to current customers, but also optimal conditions for the future growth of the acquired team.

José Antonio Martínez, CEO and Founder of Making Science, said:

"This transaction represents a strategic milestone in Making Science's evolution toward a more specialized and efficient organization. We are delighted to have found an ideal partner in Lutech, a top-tier group that guarantees the best possible future for the team and continuity of service for its clients. This agreement allows us to focus our resources on our global digital marketing and AI businesses, where we have the ability to establish sustainable leadership positions, while forging a new strategic relationship with Lutech."

Giuseppe Di Franco, CEO of Lutech Group, said:

"This acquisition is a key step in our international expansion strategy and reinforces our leadership in digital transformation services across Europe. We are impressed by the talent and expertise of the team at Making Science's Cloud, Software, and Cybersecurity unit, and we are excited to welcome them to the Lutech family. Together, we will enhance our ability to serve our clients in Spain and across Europe, and we are committed to ensuring a seamless transition for clients and investing in the team's future growth."

FINANCIAL IMPACT AND GUIDANCE

Making Science will provide more information on the planned use of the capital obtained once the transaction has been completed. In its H1 Results release dated July 31, 2025, Making Science reaffirmed its financial guidance for the fiscal year 2025. Making Science will communicate any updates to its 2025 Guidance or its 2027 Plan to the market after the transaction is completed.

ABOUT MAKING SCIENCE

Making Science is an AI-powered digital acceleration company that currently has more than 1,200 employees and a presence and technological development in 18 markets: Spain, Portugal, Mexico, Argentina, Colombia, Brazil, France, Netherlands, Italy, UK, Ireland, Sweden, Denmark, Norway, Finland, Germany, Georgia and USA. As a consulting partner of Local Planet, the world’s largest network of independent media agencies, Making Science offers digital marketing, Adtech and Martech, cloud technologies and software, and cybersecurity services globally, through delivery hubs that drive job creation and the availability of highly skilled technology talent.

Making Science is comprised of 4 business lines: the Global Digital Agency with Technology, with 360 digital advertising services that integrate strategic planning, creativity, data and technology; RAISING, the Technology Division, which combines business expertise with data science to offer advanced solutions based on AI applied to marketing; the Cloud, Software and Cybersecurity business, with a team of more than 400 engineers and data scientists for the development of cloud-based solutions and a specialised cybersecurity team; and the Making Science Investment area, with Ventis and TMQ, as a line of business diversification and implementation of the capabilities of all areas of Making Science.

RAISING, the technology division, positions the company as a global leader in digital transformation. Its proprietary solutions - ad-machina, Trust Generative AI and Gauss AI - enable brands to maximise their business results propelled by Artificial Intelligence.

In addition, the company participates in various ESG initiatives, including the Climate Pledge, the United Nations Global Compact, and the Pledge 1% initiative, supporting non-profit organisations in its community with a strong commitment to positively impacting the future.

ABOUT LUTECH

Lutech Group, a leader in Italy and a European player in digital and AI, designs, implements, and manages solutions for digital transformation, innovation, and the growth of companies and institutions, thanks to its in-depth knowledge of industry-specific processes.

With 5,500 professionals and revenues of around €1 billion, Lutech Group drives change through an end-to-end journey in which business consulting, execution, and governance maximize business results, delivering a complete and integrated offering.

Lutech expands and updates its portfolio of solutions and services through strategic acquisitions and continuous investments in people, platforms, and geographic areas.

For more information, visit www.lutech.group

View source version on businesswire.com: https://www.businesswire.com/news/home/20251007971676/en/

Contacts

Linda Cureton
makingscience@teamgingermay.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye